Janux Therapeutics, Inc. Common Stock (JANX) Stock Price

JANXStock

$18.68−23.46%52W

Market Cap$1.14B

P/E—

PEG Ratio—

Div yield—

Beta2.41

JANX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)29.56%

Price vs S&P 500 (4W)20.95%

VGM Score67.48

Book Value / Share (Quarterly)$15.19

P/TBV (Annual)1.33x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)5.12%

Cash Flow / Share (Quarterly)$-0.69

Price vs S&P 500 (YTD)22.82%

Net Profit Margin (TTM)-294.36%

EPS (TTM)$-1.64

10-Day Avg Trading Volume0.77M

EPS Excl Extra (TTM)$-1.64

EPS (Annual)$-1.83

ROI (Annual)-6.74%

Net Profit Margin (5Y Avg)-827.80%

Cash / Share (Quarterly)$15.90

Revenue Growth QoQ (YoY)2177.90%

ROA (Last FY)-6.50%

Revenue Growth TTM (YoY)5366.97%

EBITD / Share (TTM)$-2.27

ROE (5Y Avg)-29.83%

Operating Margin (TTM)-421.47%

Cash Flow / Share (Annual)$-0.75

P/B Ratio1.05x

P/B Ratio (Quarterly)1.01x

Net Income / Employee (Annual)$-1,042,400

EV / Revenue (TTM)39.60x

Net Interest Coverage (TTM)-2.49x

ROA (TTM)-10.10%

EPS Incl Extra (Annual)$-1.83

Current Ratio (Annual)60.82x

Quick Ratio (Quarterly)16.25x

3-Month Avg Trading Volume1.00M

52-Week Price Return-23.46%

Revenue / Employee (TTM)$220,200

Tangible BV / Share (Quarterly)$7.56

P/S Ratio (Annual)97.82x

Asset Turnover (Annual)0.01x

52-Week High$35.34

Operating Margin (5Y Avg)-1019.40%

EPS Excl Extra (Annual)$-1.83

26-Week Price Return40.80%

Quick Ratio (Annual)60.32x

13-Week Price Return29.08%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)16.35x

Enterprise Value$950.42M

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$91,700

Pretax Margin (Annual)-1136.25%

Cash / Share (Annual)$17.37

3-Month Return Std Dev40.39%

Net Income / Employee (TTM)$-941,200

ROE (Last FY)-6.74%

EPS Basic Excl Extra (Annual)$-1.83

Receivables Turnover (TTM)11.06x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.64

ROI (TTM)-10.79%

P/S Ratio (TTM)40.76x

Pretax Margin (5Y Avg)-827.80%

Revenue / Share (Annual)$0.16

Tangible BV / Share (Annual)$7.71

Price vs S&P 500 (52W)-41.77%

Year-to-Date Return34.78%

5-Day Price Return9.67%

EPS Normalized (Annual)$-1.83

ROA (5Y Avg)-17.92%

Net Profit Margin (Annual)-1136.25%

Month-to-Date Return22.61%

Cash Flow / Share (TTM)$-1.42

EBITD / Share (Annual)$-2.51

Operating Margin (Annual)-1576.67%

ROI (5Y Avg)-29.83%

EPS Basic Excl Extra (TTM)$-1.64

P/TBV (Quarterly)1.22x

P/B Ratio (Annual)3.02x

Pretax Margin (TTM)-294.36%

Book Value / Share (Annual)$17.34

Price vs S&P 500 (13W)26.28%

Beta2.41x

Revenue / Share (TTM)$0.38

ROE (TTM)-10.79%

52-Week Low$12.12

vGradeC

gGradeA

mGradeB

vgmGradeB

JANX Earnings Surprise History

Q2 25-0.55est. -0.47

Q3 25-0.39est. -0.61

Q4 25-0.51est. -0.64

Q1 26-0.39est. -0.52

Q2 26-0.35est. -0.29

JANX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.12

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
JANXJanux Therapeutics, Inc. Common Stock	C	A	B	$18.68
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Janux Therapeutics, Inc. Common Stock

Janux Therapeutics is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies designed to treat cancer by engaging the patient's immune system. The company has developed proprietary platforms, including TRACTr (tumor-activated T cell engagers) and TRACIr (tumor-activated immunomodulators), that combine tumor-targeting with immune activation mechanisms. These approaches aim to activate anti-cancer immune responses specifically at tumor sites, potentially improving efficacy and safety compared to conventional cancer treatments.